D-0705-2026 Class II Ongoing

Recalled by Major Pharmaceuticals — Dublin, OH

FDA drug recall D-0705-2026 was initiated by Major Pharmaceuticals on Jul 13, 2026 and is designated Class II. Reason for recall: Subpotent Drug The recall status is ongoing.

Recall details

Product Type
Drugs
Report Date
Jul 29, 2026
Initiation Date
Jul 13, 2026
Voluntary/Mandated
Voluntary: Firm initiated

Product description

Levothyroxine Sodium Tablets, USP, 125 mcg (0.0125 mg), 100 Tablets (10 x 10 unit dose blisters) per carton, Rx only, Packaged and Distributed by: MAJOR PHARMACEUTICALS, Indianapolis, IN 46268 USA. NDC: 0904-6955-61

Reason for recall

Subpotent Drug

Distribution pattern

Nationwide in the USA.

Code information

Lot #: N02266, Exp. Date 11/2026

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0705-2026
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0705-2026. Report a data issue: hello@regdatalab.com.